Guilford Street Laboratories (GSL) has successfully completed its third funding round, marking another significant milestone in the company’s growth journey in a deal advised by GS Verde – An AAB Group Company.

The round was oversubscribed, reflecting strong investor confidence in GSL’s vision, progress and future potential, with participation from both new and existing investors.

The investment will support the next phase of the company’s development, including progression through clinical validation studies in key areas such as Parkinson’s disease and hypertrophic cardiomyopathy (HCM). It will also enable the acceleration of product development and the generation of further clinical evidence.

As part of its continued expansion, Guilford Street Laboratories will establish new laboratory space at Kadans Science Partner in King’s Cross, London, a major milestone that will significantly enhance its CoreLab capabilities and support the scaling of operations.

The funding will also facilitate continued growth of the team, with additional hires planned to strengthen research and development and operational capacity.

Guilford Street Laboratories expressed its sincere thanks to all investors for their continued trust and support, with particular recognition given to Angel Invest as a key seed-stage partner that has supported the company throughout its journey.

Tomas Baldwin, CEO of GSL stated: "This funding marks a major step forward for Guilford Street Laboratories as we continue to advance a new generation of blood-based diagnostics. The strength of support from both new and existing investors reflects growing confidence in our platform, our clinical progress, and our vision to transform how complex diseases are detected and managed. With this investment, we are well positioned to accelerate clinical validation, expand our capabilities and infrastructure, and move closer to delivering impactful tests into real-world clinical settings."

The funding process was supported by GS Verde - An AAB Group Company, which provided guidance throughout the transaction.

Securing investment continues to play a critical role for high-growth life sciences businesses, enabling companies to accelerate innovation, expand capabilities and bring forward solutions that can have a meaningful impact on patient outcomes.

This latest funding round positions Guilford Street Laboratories strongly for its next phase of growth, as it continues to advance its clinical programmes and expand its scientific and operational footprint.